KEY POINTS
- Hims & Hers fell 11% to $22.29 on May 19 after announcing a $300 million convertible senior notes offering, compounding a Q1 earnings report that showed a $92.1 million net loss versus $0.03 consensus EPS.
- CEO Andrew Dudum sold 436,190 shares at $24.77 on April 13, weeks before the earnings miss, while the CFO, COO, and Chief Legal Officer also sold — a pattern that has drawn sharp scrutiny from investors.
- The company's forced pivot away from compounded GLP-1 drugs toward branded Wegovy is crushing margins, with gross margin compressing to 65% from 73% and the core U.S. business contracting 8% year over year.
Hims & Hers Health dropped 11% to $22.29 on Monday, extending a punishing selloff that has erased nearly half the stock's value since mid-April. The latest catalyst was the company's announcement of a $300 million convertible senior notes offering due 2032, which hit shares with a 7% pre-market gap-down before selling accelerated through the session. The debt deal piled onto an already toxic setup: a disastrous Q1 earnings report released May 11 and a pattern of insider selling that has left investors questioning management's confidence in its own turnaround story.
The Earnings Were Worse Than Bad
The Q1 2026 numbers were not a miss — they were a collapse. Hims reported earnings per share of negative $0.40 against a consensus expectation of positive $0.03, translating to a net loss of $92.1 million. Gross margin compressed to 65% from 73% a year earlier. Adjusted EBITDA margin cratered to 7%. The core U.S. business — the engine that was supposed to drive the company's growth narrative — contracted 8% year over year.
The damage traces to a structural shift that management had downplayed in prior quarters. Hims had built a significant revenue stream around compounded GLP-1 weight-loss drugs, which offered higher margins than branded alternatives. Regulatory pressure forced the company to pivot toward branded products like Novo Nordisk's Wegovy, a transition that crushed both the top line and margins simultaneously. The company is now spending more to acquire customers for lower-margin products, a combination that the Q1 numbers show is not working at scale.
The Insider Selling Problem
The executive selling pattern has made a bad situation worse. SEC filings show that CEO Andrew Dudum disposed of 436,190 shares at $24.77 on April 13 — roughly five weeks before the earnings release. The CFO, COO, and Chief Legal Officer also sold shares in the weeks leading up to the report. While insider sales on pre-arranged 10b5-1 plans are routine and legal, the optics of a C-suite collectively reducing exposure ahead of a quarter that would produce a 1,266% earnings miss are corrosive to investor trust.
The $300 million convertible offering announced Monday compounds the dilution concern. Convertible notes give bondholders the option to convert their debt into equity at a predetermined price, which means existing shareholders face potential dilution if the stock recovers. The timing — issuing debt just days after reporting a massive loss — suggests the company needs capital to fund its strategic pivot, and that the current cash position is insufficient to bridge the gap on its own.
Where the Floor Might Be
Hims has traded as low as $14 and as high as $58 over the past year, and at $22.29 it sits in the lower third of that range. The company still has a real business — telehealth subscriptions, dermatology, mental health services — and the GLP-1 market is enormous. The question is whether management can execute the branded-product transition without burning through cash at an unsustainable rate, and whether the convertible offering provides enough runway to get there.
Short interest has climbed significantly, and the combination of dilution risk, margin compression, and management credibility damage makes a sustained bounce difficult without a clear positive catalyst. The next scheduled earnings report for Q2 2026 will be the earliest opportunity for the company to demonstrate that the Wegovy pivot is gaining traction. Until then, the stock is in a show-me phase where every rally will be sold.
Traders looking at the long side need to see stabilization in gross margins above 65% and a halt to insider selling before taking a position. The $20 level is the next support to watch — a break below that opens the path toward the 52-week low. For now, HIMS is a cautionary tale about what happens when a high-growth narrative built on a regulatory-sensitive product line runs headlong into the reality of compliance.
